Frequently Asked Questions: HB 341 Mandatory OARRS Registration and Requests
|
|
|
- Virginia Moody
- 10 years ago
- Views:
Transcription
1 Frequently Asked Questions: HB 341 Mandatory OARRS Registration and Requests Q1) What is OARRS? Updated OARRS stands for the Ohio Automated Rx Reporting System. Established in 2006, OARRS is a web-based system that collects information on all outpatient prescriptions for controlled substances that are dispensed by Ohio licensed pharmacies and prescribed or personally furnished by licensed prescribers in Ohio. The information in OARRS is available to prescribers (or their delegates) when they treat patients, pharmacists (or their delegates) when presented with prescriptions from patients and law enforcement officers and health care regulatory boards during active investigations. Q2) When will I have to register for an OARRS account and who is required to register? Beginning January 1, 2015, Ohio law requires that each prescriber who prescribes or personally furnishes opioid analgesics or benzodiazepines, as well as all pharmacists who dispense or plan to dispense controlled substances within the state of Ohio, certify to their respective licensing board that they have registered for an OARRS account upon renewing their license. Q3) How do I register for OARRS? Registering for OARRS is now faster and easier than ever before. In 2014, the Board of Pharmacy implemented a new system to allow health care professionals (and their delegates) to register for an account as well as reset their passwords online. Using software to verify a user s identification, the registration process no longer requires a paper application and can be completed in less than 10 minutes. To get started, visit and click on the Register link at the top of the screen. You will need the following information to complete your registration: 1) driver s license number; 2) professional license number; 3) DEA License (if applicable); 4) National Provider Identifier (NPI) Number (for prescriber accounts only); and 5) office/employment information. Q4) How do I reset my OARRS password? Prescribers, pharmacists and delegates can now reset their password in one of the following three ways: 1) If you enter your login information incorrectly 3 times, you will be automatically redirected to the password reset page. 2) If you are already locked out and attempt to login, you will be automatically redirected to the password reset page. 1
2 3) Click the forgot your password link on the OARRS homepage with your user name entered into the correct field and you will be taken to the password reset (see image below). Once directed to the password reset page, you will be asked to confirm your identity by answering three questions. Once answered correctly, you will be prompted to choose a new password. Q5) As a prescriber, under what circumstances am I required to request, assess and document receipt of a patient s OARRS prescription history report? Beginning April 1, 2015, Ohio law establishes several new requirements for Ohio prescribers related to the Ohio Automated Rx Reporting System (OARRS): Before initially prescribing or personally furnishing an opioid analgesic or a benzodiazepine to a patient, the prescriber must request patient information from OARRS that covers at least the previous 12 months. The prescriber must also make periodic requests for patient information from OARRS if the course of treatment continues for more than 90 days. Under the circumstances described above, the prescriber is required to assess the OARRS information and document in the patient record that a patient prescription history report was received and assessed. Please note: A recent change in Ohio law no longer requires an optometrist holding a therapeutic pharmaceutical agents certificate to query OARRS in the situations listed above. However, an optometrist holding a therapeutic pharmaceutical agents certificate must comply with rule of the Administrative Code regarding when to access information in OARRS. Q6) Are there any exceptions to the law? Yes. Exceptions to mandatory checks prior to prescribing an opioid analgesic or benzodiazepine include the following scenarios: The drug is prescribed or personally furnished to a hospice patient or to any other patient who has been diagnosed as terminally ill (all prescribers except optometrists); 2
3 The drug is prescribed or personally furnished in an amount indicated for a period not to exceed seven days (all prescribers except optometrists); The drug is prescribed or personally furnished for the treatment of cancer or another condition associated with cancer (advanced practice registered nurses, physician assistants, and physicians but not dentists and optometrists); The drug is prescribed or personally furnished for administration in a hospital, nursing home, or residential care facility (advanced practice registered nurses, physician assistants, and physicians but not dentists and optometrists); The drug is prescribed or personally furnished to treat acute pain resulting from a surgical or other invasive procedure or a delivery (physicians only); and The OARRS report is not available (all prescribers). Q7) How do I document that I have run a report? A prescriber who is required to review OARRS information must document in the patient's medical record that the report was received and the information was assessed. If for some reason the OARRS report is not available, the prescriber should document in the record when the report was requested and its unavailability. Q8) I will not renew my license until after April 1, 2015, will I be required to request, assess and document receipt of a patient s OARRS prescription history report as outlined above? Yes. Beginning April 1, 2015, you will be required to query OARRS as outlined in Q5 and Q6 of this document. While you may not be required to attest that you have registered with the system prior to April 1, 2015, it is strongly recommended that all prescribers who prescribe or personally furnish opioid analgesics or benzodiazepines register with the system (see Q3 of this document for more information on registration). Q9) As a prescriber practicing in a county adjoining another state, am I required to check another state s prescription monitoring program? Yes. Beginning April 1, 2015, if you are a prescriber who practices primarily in an Ohio county that adjoins another state, Ohio law requires you to request the adjoining state s prescription drug information, which can be easily accessed through OARRS. Please note that Pennsylvania does not currently have a prescription monitoring program at this time. If one should become operational, then prescribers in counties adjoining Pennsylvania would be required to access the system. The following is a table to assist prescribers practicing in counties that adjoin another state in identifying the required interstate selections in OARRS: County of Practice Adams Required Interstate Selection(s) Kentucky 3
4 Athens Belmont Brown Butler Clermont Darke Defiance Fulton Gallia Hamilton Jefferson Lawrence Lucas Meigs Mercer Monroe Paulding Preble Scioto Van Wert Washington Williams Kentucky Kentucky Michigan Kentucky,, Kentucky Michigan Kentucky, Michigan REMINDER: PENNSYLVANIA DOES NOT HAVE AN ACTIVE PRESCRIPTION MONITORING PROGRAM AT THIS TIME. IF ONE SHOULD BECOME OPERATIONAL, THEN PRESCRIBERS IN COUNTIES ADJOINING PENNSYLVANIA WOULD BE REQUIRED TO ACCESS THE SYSTEM. Q10) I am a physician assistant, how do I access prescription information provided from Kentucky s prescription monitoring program, KASPER (Kentucky All Schedule Prescription Electronic Reporting)? Under Kentucky law, a physician assistant is not considered a prescriber and cannot access the system using their own account. Therefore, those physician assistants who have an OARRS prescriber account are not permitted to access KASPER information. An Ohio physician assistant that wishes to access Kentucky s PMP in OARRS will have to do so using a delegate account. Q11) Is there a definition for opioid analgesics and benzodiazepines available? 4
5 Effective March 20, 2015, section of the Ohio Revised Code defines an opioid analgesic as a controlled substance that has analgesic pharmacologic activity at the opioid receptors of the central nervous system, including the following drugs and their varying salt forms or chemical congeners: Generic Name Brand Name Schedule Buprenorphine BUTRANS, BUPRENEX Schedule III Butorphanol BUTORPHANOL NS Schedule IV Codeine (acetaminophen and TYLENOL W. CODEINE #3, TYLENOL Schedule III other combination products) W. CODEINE #4 Dihydrocodeine/ASA/caffeine SYNALGOS-DC Schedule III Fentanyl DURAGESIC, ACTIQ, ABSTRAL, Schedule II LAZANDA, FENTORA, SUBSYS, SUBLIMAZE, ONSOLIS, IONSYS Hydrocodone ZOHYDRO ER Schedule II Hydrocodone (acetaminophen combination products) XODOL, MAXIDONE, ZYDONE, LORCET, HYCET, ZAMICET, CO- GESIC, ZOLVIT, STAGESIC, LIQUICET, LORTAB, VICODIN, NORCO IBUDONE, REPREXAIN, VICOPROFEN Hydrocodone (ibuprofen Schedule II combination products) Hydromorphone DILAUDID, EXALGO Schedule II Meperidine DEMEROL Schedule II Methadone DOLOPHINE, METHADOSE Schedule II Morphine Sulfate MS CONTIN, AVINZA, DURAMORPH, Schedule II KADIAN, DEPODUR, ASTRAMORPH, IMFUMORPH Oxycodone OXECTA, ROXICODONE, OXYCONTIN Schedule II Oxycodone (acetaminophen, aspirin and other combination products) PERCODAN, PERCOCET, ROXICET, ENDOCET, XOLOX, TYLOX, PRIMLEV, MAGNACET, XARTEMIS XR Schedule II (Effective October 6, 2014) Schedule II Oxymorphone OPANA, NUMORPHAN Schedule II Tapentadol NUCYNTA Schedule II Tramadol ULTRAM, ULTRACET, RYZOLT, CONZIP, RYBIX Schedule IV (Effective August 18, 2014) Effective March 20, 2015, section of the Ohio Revised Code defines a benzodiazepine as a controlled substance that has United States Food and Drug Administration (FDA) approved labeling indicating that it is a benzodiazepine, benzodiazepine derivative, triazolobenzodiazepine, 5
6 or triazolobenzodiazepine derivative, including the following drugs and their varying salt forms or chemical congeners: Generic Name Brand Name Schedule FDA Label Alprazolam ALPRAZOLAM, XANAX, NIRAVAM Schedule IV Chlordiazepoxide A-POXIDE, CHLOR POX, CHLORDIA-XE CHLORDIAZEPOXIDE, CHLORDIAZEPOXIDE HCL CHLORDIAZEPOXIDE HYDROCHLORIDE, LIBACA, LIBRITABS, LIBRIUM, MITRAN, POXI, REPOSANS-10, RO-POXIDE, SEREEN, SK- Hydrochloride LYGEN, SPAT-10, SPAZ-10, SPAZ-5 Schedule IV Clobazam ONFI Schedule IV Clonazepam CLONAZEPAM, CLONAZEPAM, KLONOPIN Schedule IV Clorazepate Dipotassium CLORAZEPATE, CLORAZEPATE DIPOTASSIUM, GEN-XENE, TRANXENE, TRANXENE T-TAB, TRANXENE-SD Schedule IV Dextrose/Lorazep am LORAZEPAM-DEXTROSE Schedule IV Dextrose/Midazol am Hydrochloride MIDAZOLAM-DEXTROSE Schedule IV DIASTAT, DIASTAT ACUDIAL, DIASTAT PEDIATRIC, DIASTAT UNIVERSAL, DIAZEPAM, DIAZEPAM INTENSOL, DIAZEPAM RECTAL DELIVERY SYSTEM, DIZAC, D-VAL, ED- VAL, Q-PAM, RO-AZEPAM, T-QUIL, VALIUM, VALRELEASE, X-O SPAZ, ZETRAN Derivative Diazepam Schedule IV Triazolobenzodiazepine Estazolam ESTAZOLAM, PROSOM Schedule IV Derivative Flurazepam DALMANE, FLURAZEPAM Hydrochloride HYDROCHLORIDE, FLURAZEPAM Schedule IV ATIVAN, LORAZ, LORAZEPAM, LORAZEPAM AMERINET, NOVAPLUS LORAZEPAM, PROBATE, LORAZEPAM- Lorazepam SODIUM CHLORIDE Schedule IV Midazolam MIDAZOLAM, MIDAZOLAM HCL AMERINET CHOICE, MIDAZOLAM HYDROCHLORIDE, NOVAPLUS MIDAZOLAM HYDROCHLORIDE, VERSED, MIDAZOLAM HYDROCHLORIDE-SODIUM CHLORIDE Schedule IV Oxazepam OXAZEPAM, SERAX Schedule IV Quazepam DORAL, DORMALIN Schedule IV Temazepam RESTORIL, TEMAZ, TEMAZEPAM Schedule IV Triazolam HALCION, TRIAZOLAM Schedule IV Triazolobenzodiazepine Q12) Can a delegate run a patient s OARRS report on behalf of the prescriber in order satisfy the requirements of the law listed in Q5 of this document? 6
7 Yes. A delegate who runs a report on behalf of a prescriber will satisfy the requirements of the law listed in Q5 of this document. However, the delegate may only run a patient s prescription history report and is not permitted to interpret the results. Please note that delegates must have their own OARRS account with their own unique user name and password. They may not run the report under the prescriber s user name and password. The law requires documentation in the patient s medical record that the report was received and the information was assessed. To register for a delegate account: 1) Go to 2) Click on the register button at the top of the page; 3) Follow the prompts for delegates to complete the registration. Once the delegate account is created, the delegate will need to inform the supervising prescriber or pharmacist of their username so the supervisor can link the accounts (see Q13). Q13) How do I add or remove delegates from my account? For prescribers and pharmacists to add or remove delegates, complete the following steps: 1. Log into your account by visiting Click on Related Links and select Automated Add/Remove Delegate. 2. You will then be required to complete authentication questions. 3. You can then click the Remove Delegate button next to the delegates you wish to remove or enter the user name of the delegates you wish to add. 7
8 IMPORTANT: YOU CANNOT USE THIS FUNCTION TO ADD A DELEGATE WHO DOES NOT HAVE AN EXISTING OARRS ACCOUNT. Q14) Who can serve as a prescriber or pharmacist delegate? For the purposes of OARRS, any individual who is either supervised or employed by a prescriber or pharmacist can serve as their delegate. For more information on the roles and responsibilities of a delegate, please review the delegate acceptable use policies here: Q15) How many delegates can I have? The Ohio State Board of Pharmacy has determined that a prescriber or pharmacist may have as many delegates as they believe they can adequately supervise. It is up to the supervising prescriber or pharmacist to decide how many delegates they designate. Q16) I work in a group practice. Can I have my delegates run OARRS reports for other prescribers in the practice? No. Only delegates added to a prescriber s account can run OARRS for that prescriber s patients. This ensures a delegate is not accessing unauthorized patient information. In this situation, it is recommended that delegates are added to all prescriber accounts in the existing practice setting. A delegate can be added to more than one prescriber or pharmacist account (see Q13). Q17) I am a prescriber that holds an Ohio license but practices out of state. Am I required to register for an OARRS account? No. Only prescribers that practice in the state of Ohio are required to obtain an OARRS account Q18) I am a pharmacist who maintains an Ohio license but does not practice pharmacy. Am I required to register for an OARRS account? No. Only pharmacists who dispense controlled substances to patients residing in Ohio are required to register for an OARRS account. Q19) I am a pharmacy intern. Am I required to register for an OARRS account? No. Only pharmacists who dispense controlled substances to patients residing in Ohio are required to register for an OARRS account. Pharmacy interns are permitted to obtain delegate accounts under the oversight of a practicing pharmacist. Q20) Can I include an OARRS prescription history report in the patient s medical chart? Yes. Effective March 20, 2015, Ohio law permits a prescriber or pharmacist to include an OARRS report as part of the patient s medical record. Once included in the chart, the report is deemed part of the medical record subject to disclosure on the same terms and conditions as listed in section of the Revised Code. 8
9 Q21) Can I review a patient s OARRS report with the patient or a patient s representative? Yes. An Ohio prescriber or pharmacist can review the information included in an OARRS report with a patient. Q22) I am an optometrist holding a therapeutic pharmaceutical agents certificate. Under what circumstances am I required to request, assess and document receipt of a patient s OARRS prescription history report? Ohio law no longer requires an optometrist holding a therapeutic pharmaceutical agents certificate to meet the requirements listed in Q5 of this document. However, an optometrist holding a therapeutic pharmaceutical agents certificate is still required to register for an OARRS account if they practice within the state of Ohio and if prescribe or personally furnish opioid analgesics. In addition, an optometrist holding a therapeutic pharmaceutical agents certificate must comply with rule of the Ohio Administrative Code regarding when to access information in OARRS. Q23) Who do I contact for more information? If you are a pharmacist, pharmacy intern, location licensed as a terminal distributor of dangerous drugs or have an OARRS account-related question, please contact the Ohio State Board of Pharmacy at or visit If you are a prescriber, please contact your respective regulatory board using the information below. State Medical Board of Ohio: (614) Ohio Board of Nursing: [email protected] Ohio State Dental Board: (614) Ohio State Optometry Board: (614)
Opioids to Minors and Drug Donation Programs Objectives By completing the lesson, the pharmacist will be able to:
1 1 1 1 1 1 0 1 0 1 Opioids to Minors and Drug Donation Programs Objectives By completing the lesson, the pharmacist will be able to: Discuss Ohio s new laws concerning use of opioids in minors Describe
GAO MEDICARE PART D. Instances of Questionable Access to Prescription Drugs. Report to Congressional Requesters
GAO United States Government Accountability Office Report to Congressional Requesters September 2011 MEDICARE PART D Instances of Questionable Access to Prescription Drugs GAO-11-699 September 2011 MEDICARE
MUSC Opioid Analgesic Comparison Chart
MUSC Opioid Analgesic Comparison Chart Approved by the Pharmacy and Therapeutics Committee (February 2006, November 2009, March 2010, December 2011) Prepared by the MUSC Department of Pharmacy Services
Opiates Heroin/Prescription Steve Hanson Opiates Dates to 4,000 BC Mimics endorphin activity Natural - Opium, morphine, codeine Semi-synthetic- Heroin, Dilaudid Synthetics - Darvon, Demerol, Fentanyl Modern
How To Understand The Health Effects Of Prescription Drugs
Miami-Dade, Broward and Palm Beach Counties, Florida Trends of Nonmedical Prescription Drug Misuse in Miami-Dade, Broward, Palm Beach Counties, and the State of Florida: 2010 James N. Hall 1 ABSTRACT The
2015 REPORT Steven W. Schierholt, Esq. Executive Director www.pharmacy.ohio.gov
OHIO AUTOMATED RX REPORTING SYSTEM 2015 REPORT Steven W. Schierholt, Esq. Executive Director www.pharmacy.ohio.gov OHIO AUTOMATED RX REPORTING SYSTEM What is OARRS? To address the growing misuse and diversion
Prescription drug abuse trends. Minnesota s Prescription Monitoring Program. Minnesota Rural Health Conference June 25, 2013 Duluth
Prescription drug abuse trends Minnesota s Prescription Monitoring Program Carol Falkowski Drug Abuse Dialogues www.drugabusedialogues.com Barbara Carter, Manager MN Board of Pharmacy www.pmp.pharmacy.state.mn.us
CIINCINNATI POLICE PHARMACEUTICAL DIVERSION SQUAD HEALTH CARE PROFESSIONAL INVESTIGATIONS
CIINCINNATI POLICE PHARMACEUTICAL DIVERSION SQUAD HEALTH CARE PROFESSIONAL INVESTIGATIONS CINCINNATI POLICE PHARMACEUTICAL DIVERSION SQUAD Kelly Raker 310 Ezzard Charles Dr. Cincinnati, OH 45214 513-564-2233
Roadmap. Florida Trends in Prescription Drug Abuse. Oath of a Pharmacist. Plantation Chemist Busted
Florida Trends in Prescription Drug Abuse Jennifer A. Fass, PharmD, CPh Clinical Assistant Professor [email protected] Roadmap Discuss Florida Medical Examiners Report Illustrate prescription drug abuse cases
American Indian Health Commission for Washington State October 1, 2015
American Indian Health Commission for Washington State October 1, 2015 States with more opioid pain reliever sales tend to have more drug overdose deaths Death rate, 2011, National Vital Statistics System.
FLORIDA DEPARTMENT OF LAW ENFORCEMENT SEPTEMBER 2013. 2012 Report
FLORIDA DEPARTMENT OF LAW ENFORCEMENT SEPTEMBER 2013 2012 Report Data Collection The Office of Vital Statistics reported more than 178,000 deaths occurred in Florida during 2012. Of these, the medical
Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain (CNCP)
Appendix D: Urine Drug Testing for Monitoring Opioid Therapy i. Monitoring opioid therapy with urine drug testing (UDT) ii. UDT algorithm for monitoring opioid therapy iii. UDT clinical vignettes iv. Frequently
PtProtect Pain Medication Management Program Monitors Patient Compliance
PHYSICIAN UPDATE 2013 Edition PtProtect Pain Medication Management Program Monitors Patient Compliance The PtProtect (Patient Protect) program offers pain medication management panels designed to improve
New Jersey EMS Response to an Opiate Overdose Naloxone (Narcan ) Program **Updated March 26, 2015**
New Jersey EMS Response to an Opiate Overdose Naloxone (Narcan ) Program **Updated March 26, 2015** Disclaimer This presentation was created to assist in the education of EMTs in Naloxone administration.
INFO Brief. Prescription Opioid Use: Pain Management and Drug Abuse In King County and Washington State
ADAI-IB 23-3 INFO Brief Prescription Opioid Use: Pain Management and Drug Abuse In King County and Washington State O ctober 23 Caleb Banta-Green (Alcohol and Drug Abuse Institute, University of Washington),
The TIRF REMS Access program is a Food and Drug Administration (FDA) required risk management program
Subject: Important Drug Warning Announcement of a single shared REMS (Risk Evaluation and Mitigation Strategy) program for all Transmucosal Immediate Release Fentanyl (TIRF) products due to the potential
What Parents Need to Know
What Parents Need to Know About Prescription Drug Abuse Office of District Attorney Jonathan W. Blodgett A Message From the District Attorney Prescription drug abuse is a growing problem. According to
CITY OF MONTEREY Substance Abuse Policy General Employees of Monterey (GEM) July 1, 2003
Page 1 ATTACHMENT C CITY OF MONTEREY Substance Abuse Policy General Employees of Monterey (GEM) July 1, 2003 PURPOSE This policy provides guidelines for the detection and deterrence of alcohol and drug
Practitioner s Manual
United States Department of Justice Drug Enforcement Administration Office of Diversion Control An Informational Outline of the Controlled Substances Act Joseph T. Rannazzisi Deputy Assistant Administrator
Oral Fluid Drug Testing March 23 rd, 2015
Oral Fluid Drug Testing March 23 rd, 2015 Drug Testing Options Breath Blood Meconium Vitreous Hair Sweat Urine Oral Drug Testing Options Oral Fluid and Blood and Breath Actual levels (immediate use, up
Equianalgesic Dosing of Opioids for Pain Management
PL Detail-Document #280801 This PL Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER August 2012 Equianalgesic Dosing of Opioids for Pain Management
URINE DRUG TEST INFORMATION SHEET BENZODIAZEPINES
URINE DRUG TEST INFORMATION SHEET BENZODIAZEPINES Classification: Central nervous system depressants (CNS depressants) Background: Benzodiazepines are a large group of drugs that act as central nervous
Information for Vermont Prescribers of Prescription Drugs (Long Form)
The information on this form is provided pursuant to Vermont law 33 V.S.A. section 2005a which requires this disclosure by pharmaceutical marketers. Information for Vermont Prescribers of Prescription
Prescribers required to check PDMP before first prescription for Controled Substances for new patient.
State, District, or Territory Alabama Arizona Arkansas Colorado Connecticut Delaware Georgia Guam Criteria for Mandatory Enrollment or Query of PDMP Before renewing an Alabama Controlled Substances Certificate,
A Healthesystems Clinical Analysis. Insidious Incrementalism of Opioid Use in Workers Compensation
A Healthesystems Clinical Analysis Insidious Incrementalism of Opioid Use in Workers Compensation Prescription opioid use in the United States has grown significantly over the past 20 years. In 1991, there
SMART DISCHARGE. Client s Name: Client ID: Partial Hospitalization Clinically Managed Medium Intensity Residential Treatment
SMART DISCHARGE Client s Name: Client ID: DATE OF DISCHARGE: Reason for Discharge Completed Treatment no further treatment needed Completed Treatment Plan/Referred Incomplete Client Left Before Completing
State of Louisiana. Department of Health and Hospitals Bureau of Health Services Financing
Bobby Jindal GOVERNOR Bruce D. Greenstein SECRETARY State of Louisiana Department of Health and Hospitals Bureau of Health Services Financing Re: Quantity Limits, Maximum Dosages and ICD-9-CM Diagnosis
Drug Abuse Trends in Miami-Dade and Broward Counties, South Florida: June 2013 James N. Hall 1
Drug Abuse Trends in Miami-Dade and Broward Counties, South Florida: June 2013 James N. Hall 1 ABSTRACT Significant shifts in drug abuse patterns are underway. Cocaine consequences have stabilized or increased
PRESCRIPTION PAINKILLER OVERDOSES
IMPACT{ POLICY PRESCRIPTION PAINKILLER OVERDOSES National Center for Injury Prevention and Control Division of Unintentional Injury Prevention What s the Issue? In a period of nine months, a tiny Kentucky
Drug Utilization Is On The Rise
Objectives Identify the clinical issues related to opioid prescribing for chronic pain indications Define the clinical needs and expectations of urine drug testing in pain management Address preanalytical
What Is a Prescriber s Role in Preventing the Diversion of Prescription Drugs?
What Is a Prescriber s Role in Preventing the Diversion of Prescription Drugs? 2 CONTENT SUMMARY Drug diversion is the illegal distribution or abuse of prescription drugs or their use for unintended purposes.
Reducing Narcotics Misuse and Abuse in Workers Compensation
Reducing Narcotics Misuse and Abuse in Workers Compensation Trusted. Reliable. Sustainable. Page 2 Introduction Narcotics have a long history of being used to therapeutically treat pain resulting from
1. Carrying Personal Medications into Thailand A. Medications containing narcotic drugs of category 2
Guidance for Travellers to Thailand under Treatment Carrying Personal Medications Containing Narcotic Drugs/Psychotropic Substances into/out of Thailand This guidance issued by the Narcotics Control Division,
OBJECTIVES. ! Understand the rising epidemic of prescription drug abuse in Wyoming. ! Know how to access and use reports from the WORx program
Full source: Wyoming Survey & Analysis Center (2013). Wyoming Prevention Needs Assessment: Interactive Graphing. Laramie, WY: University of Wyoming. (http://pnasurvey.org) Full Source: Wyoming Department
SAFE PAIN MEDICATION PRESCRIBING GUIDELINES
Prescription drug abuse has been declared an epidemic by the Centers for Disease Control. According to 2012 San Diego Medical Examiner data, the number one cause of non-natural death is due to drug overdoses
PARTNERSHIP HEALTHPLAN RECOMMENDATIONS For Safe Use of Opioid Medications
PARTNERSHIP HEALTHPLAN RECOMMENDATIONS For Safe Use of Opioid Medications Primary Care & Specialist Prescribing Guidelines Introduction Partnership HealthPlan is a County Organized Health System covering
Prescription Drug Reference Guide For Pain Management Physicians
Prescription Drug Reference Guide For Pain Management Physicians Provided by Quality Results You Can Count On! 121 N. 20 th Street, Bldg. 17 Opelika, AL 36801 (877) 364-9851 (334) 528-4310 fax PRESCRIPTION
Mid-Level Practitioners Authorization by State
Mid-Level Practitioners Authorization by State Pursuant to Title 21, Code of Federal Regulations, Section 1300.01(b28), the term mid-level practitioner means an individual practitioner, other than a physician,
Drug Abuse Trends in Miami-Dade and Broward Counties, South Florida: June 2014
Drug Abuse Trends in Miami-Dade and Broward Counties, South Florida: June 2014 James N. Hall 1 ABSTRACT The key finding for this reporting period is that there has been substantial progress in reducing
Visit www.takebackmylife.org to hear more of my story or call 211 for help and treatment options
In high school, I experimented with alcohol and pot. Then I moved on to narcotics and cocaine, which landed me in jail several times. By 25, I was a daily heroin user with a long-term prison sentence.
Testimony Engrossed House Bill 1101 Department of Human Services Senate Human Services Committee Senator Judy Lee, Chairman February 19, 2013
Testimony Engrossed House Bill 1101 Department of Human Services Senate Human Services Committee Senator Judy Lee, Chairman February 19, 2013 Chairman Lee, members of the Senate Human Services Committee,
Massachusetts Substance Abuse Policy and Practices. Senator Jennifer L. Flanagan Massachusetts Worcester and Middlesex District
Massachusetts Substance Abuse Policy and Practices Senator Jennifer L. Flanagan Massachusetts Worcester and Middlesex District November 2014 Substance Abuse and Addiction National and State opioid abuse
Drug Abuse Trends in Miami-Dade County, Florida: 2009-2010
Drug Abuse Trends in Miami-Dade County, Florida: 2009-2010 James N. Hall 1 ABSTRACT Cocaine consequences as a proportion of all drug problems continue to be higher in South Florida than in most of the
Ultram (tramadol), Ultram ER (tramadol extended-release tablets); Conzip (tramadol extended-release capsules), Ultracet (tramadol / acetaminophen)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.35 Subject: Tramadol Acetaminophen Page: 1 of 8 Last Review Date: September 18, 2015 Tramadol Acetaminophen
Prescription Drug Abuse and Pain Management Clinics 2015 Report to the 109 th Tennessee General Assembly
Prescription Drug Abuse and Pain Management Clinics 2015 Report to the 109 th Tennessee General Assembly Andrea Huddleston, Chief Deputy General Counsel Tennessee Department of Health Office of General
There will be no refunds once services are performed.
WEIGHT LOSS NEW PATIENT PAPERWORK PATIENT: Name: Last First Address: City: State: Zip Phone: ( ) Alt #( ) Email: DOB: Age: Sex: Occupation: EMERGENCY CONTACTS: (You must list at least one person) Name:
How To Get A Prescription In Rhode Island
Controlled Substance Prescribing Laws, The Prescription Monitoring Program, and Preventing Drug Diversion Michael Halse, PharmD PGY1 Resident Pharmacist South County Hospital and Healthcare System Disclosures
Practice Protocol. Buprenorphine Guidance Protocol
Practice Protocol Buprenorphine Guidance Protocol Developed by the Arizona Department of Health Services Division of Behavioral Health Services Effective Date: 02/23/11 Title Buprenorphine Guidance Protocol
Who is the DEA? New Narcotic Regulations and How They Affect Your Assisted Living Facility. 2009 DEA Audits. Scheduled/Controlled Drugs
Who is the DEA? New Narcotic Regulations and How They Affect Your Assisted Living Facility Nancy Lamb RPh Good Day Pharmacy DEA- Drug Enforcement Administration This is not the State Health Department
What Does the Drug Test Tell Us
What Does the Drug Test Tell Us QUALITATIVE TOXICOLOGY TESTING for CLINICAL MANAGEMENT of the PATIENT Background The qualitative drug test is often referred to as the drug screen - a misnomer Testing performed
PMP AWAR X E. User Support Manual V 1.2
PMP AWAR X E User Support Manual V 1.2 04/09/2014 1 Contents 1 What Is a Requestor?... 3 2 Registration... 3 2.1 Registration Process... 3 2.2 Registering as a Delegate... 7 2.3 Email Verification... 11
Exceptions to the Rule: A Pharmacy Law Presentation. Objectives DISCLAIMER 10/16/2015
Exceptions to the Rule: A Pharmacy Law Presentation Eric Roath, Pharm.D. Director of Professional Practice Michigan Pharmacists Association Objectives 1. Identify basic legal frameworks that govern the
Prescriptive and Dispensing Authority in Oregon
Oregon State Board of Nursing Prescriptive and Dispensing Authority in Oregon For Advanced Practice Registered Nurses 11/2015 Welcome to the State of Oregon! This booklet reviews laws and regulations regarding
An Overview of Risk Evaluation and Mitigation Strategy (REMS): Elements Related to Medication Use and Dispensing
INDIANA PHARMACISTS ALLIANCE (IPA) CONTINUING PHARMACY EDUCATION (CPE) 2012 Article #9 An Overview of Risk Evaluation and Mitigation Strategy (REMS): Elements Related to Medication Use and Dispensing Authors:
TRANSMUCOSAL IMMEDIATE RELEASE FENTANYL (TIRF) RISK EVALUATION AND MITIGATION STRATEGY (REMS)
Initial REMS approval: 12/2011 Most recent modification: /2014 TRANSMUCOSAL IMMEDIATE RELEASE FENTANYL (TIRF) RISK EVALUATION AND MITIGATION STRATEGY (REMS) Page 1 of 16 I. GOALS The goals of the TIRF
THE LAWS AND REGULATIONS ON APRN PRESCRIPTIVE AUTHORITY
THE LAWS AND REGULATIONS ON APRN PRESCRIPTIVE AUTHORITY KRS 314.011(8) "Advanced practice registered nursing" means the performance of additional acts by registered nurses who have gained added knowledge
POST-TEST Pain Resource Professional Training Program University of Wisconsin Hospital & Clinics
POST-TEST University of Wisconsin Hospital & Clinics True/False/Don't Know - Circle the correct answer T F D 1. Changes in vital signs are reliable indicators of pain severity. T F D 2. Because of an underdeveloped
Good Practice Guidance: The safe management of controlled drugs in care homes
Good Practice Guidance: The safe management of controlled drugs in care homes Medicines Management Social Care Support Team Reviewed April 2015 Good Practice Guidance: The safe management of controlled
Protecting Your Practice and Patients Tackling Prescription Drug Abuse Accreditation Pharmacists: 0798-0000-12-040-L05-P Nurses: N-764
Page 1 Protecting Your Practice and Patients Tackling Prescription Drug Abuse Accreditation Pharmacists: 0798-0000-12-040-L05-P Nurses: N-764 CE Credit(s) 1.0 contact hour(s) Protecting Your Practice and
NORFOLK SOUTHERN MEDICAL DEPARTMENT RESOURCE BOOK FOR EMPLOYEES
NORFOLK SOUTHERN MEDICAL DEPARTMENT RESOURCE BOOK FOR EMPLOYEES Norfolk Southern Medical Department (NSMD) resources listed below provide you with direct contact information for your assigned NSMD case
Understanding Your Pain
Toll Free: 800-462-3636 Web: www.endo.com Understanding Your Pain This brochure was developed by Margo McCaffery, RN, MS, FAAN, and Chris Pasero, RN, MS, FAAN authors of Pain: Clinical Manual (2nd ed.
A Handbook to Help You Succeed in the Washington Recovery and Monitoring Program (WRAMP)
Washington Recovery and Monitoring Program Post Office Box 47852, Olympia, WA 98504 7852 Telephone: 360-236-2880 Fax: 360-236-4704 A Handbook to Help You Succeed in the Washington Recovery and Monitoring
Heroin Addiction. Kim A. Drury RN, MSN
Heroin Addiction Kim A. Drury RN, MSN Heroin use is on the rise in our area. Nearly every day the news media reports situations involving Heroin. According to the Substance Abuse and Mental Health Services
Colorado Prescription Drug Monitoring Program. Department of Regulatory Agencies Division of Professions and Occupations State Board of Pharmacy
Colorado Prescription Drug Monitoring Program Department of Regulatory Agencies Division of Professions and Occupations State Board of Pharmacy DORA is dedicated to preserving the integrity of the marketplace
22 nd National Conference Pharmaceutical and Chemical Diversion. Pharmaceutical Drug Abuse & Trafficking Trends September 30, 2014
22 nd National Conference Pharmaceutical and Chemical Diversion Pharmaceutical Drug Abuse & Trafficking Trends September 30, 2014 Ruth A. Carter, Chief Liaison and Policy Section [email protected]
New Mexico Drug Donation Guide
New Mexico Drug Donation Guide 16.19.34.2 SCOPE: This section applies to licensed clinics and participating practitioners located within the state of New Mexico who provide for the donation and redistribution
Kentucky All Schedule Prescription Electronic Reporting (KASPER)
Kentucky All Schedule Prescription Electronic Reporting (KASPER) A Comprehensive Report on Kentucky s Prescription Monitoring Program Prepared by the Cabinet for Health and Family Services Office of the
MAPS. Michigan Automated Prescription System 2012 Statistics/DEA Analysis /Board of Pharmacy Updates
MAPS Michigan Automated Prescription System 2012 Statistics/DEA Analysis /Board of Pharmacy Updates Key Messages What: The Michigan Automated Prescription System (MAPS) is the prescription monitoring program
Drug Trends Analysis. Drug Utilization and Spending Trends in Workers Compensation
2013 Drug Trends Analysis Drug Utilization and Spending Trends in Workers Compensation Inside Introduction... 1 Understanding Total Pharmacy Spend... 2 New Drugs, New Generics and What s New in 2014...
How to Utilize the Security Portal to Access PDMP (User Guide for Practitioners, Pharmacists, CRNPs, Physician Assistants, Law Enforcement, and CNMs)
How to Utilize the Security Portal to Access PDMP (User Guide for Practitioners, Pharmacists, CRNPs, Physician Assistants, Law Enforcement, and CNMs) July 30, 2014 Version 2 Software Release Version 3.4.11
Prescription Drug Monitoring Program. A Powerful Tool
Prescription Drug Monitoring Program A Powerful Tool September 16, 2015 No reportable financial interest. Controlled Substance Utilization Review and Evaluation System >16,000 Prescription Painkiller Overdose
State of South Dakota Board of Pharmacy Prescription Drug Monitoring Program. User Support Manual
State of South Dakota Board of Pharmacy Prescription Drug Monitoring Program User Support Manual Contents 1 What Is a Requestor?... 3 2 Registration... 4 2.1 Registration Process... 4 2.2 Registering as
